MUNDIPHARMA ADDS ELIGARD® TO ONCOLOGY PORTFOLIO WITH THE ACQUISITION OF TOLMAR AUSTRALIA PTY LIMITED

Singapore, 19 February 2018: Mundipharma has today announced the acquisition of specialist pharmaceutical company, Tolmar Australia Pty Limited, (“Tolmar”), including exclusive distribution rights for the oncology medication Eligard® (leuprorelin acetate) in Australia and New Zealand following several months of comprehensive due diligence and negotiation. The acquisition includes the oncology medications Eligard® and Bi-Eligard …